Company News: Pfizer

Share this article:
Pfizer said it will supply its Prevnar 13 pediatric vaccine to impoverished countries for 10 years under the terms of a UNICEF pilot project aimed at fighting pneumococcal disease, the leading cause of vaccine-preventable death for children under 5 globally. Under the terms of an Advance Market Committment agreement, Pfizer has agreed to charge no more than $3.50 per dose for 10 years to meet long-term demand and ensure affordability of the vaccine in developing countries even after the donor contributions are exhausted.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.